Skip to main content
Premium Trial:

Request an Annual Quote

BioMarker Strategies Lands $2.3M in NCI SBIR Grants

NEW YORK (GenomeWeb) – BioMarker Strategies announced it has landed two small business innovation research (SBIR) grants from the National Cancer Institute.

The Rockville, Maryland-based companion diagnostics firm has already received a six month $300,000 Phase I grant and has recently been awarded a two year, $2 million Phase II grant to develop a companion diagnostic for non-small cell lung cancer therapies.

The Phase II grant will begin once the firm reaches predetermined milestones set in the Phase I grant project, which is currently underway, the firm said in a statement.

BioMarker Strategies' PathMap functional signaling profiles technology uses live cells to provide information on resistance to therapy. It is based on the firm's proprietary SnapPath platform, which is used for ex vivo profiling of live solid tumor cells from fresh, unfixed samples.

SnapPath was also borne out of NCI SBIR grants totaling $2.3 million, awarded to BioMarker Strategies in 2010.